Sergei Gryaznov
Known title: Chief Scientific OfficerCIK: 0001913228
Sergei Gryaznov's purchase track record
Sergei Gryaznov has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/1/2026 | MAIA | $3K | +0.8% | pending | — |
| 8/1/2022 | MAIA | $15K | -53.2% | -39.9% | -2.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MAIA | ▲ Buy | Open Market | 2,000 | $3K | 6/1/2026 | View on chart |
| MAIA | ▲ Buy | Option Exercise | 10,000 | $18K | 12/7/2022 | View on chart |
| MAIA | ▲ Buy | Option Exercise | 10,000 | $18K | 8/24/2022 | View on chart |
| MAIA | ▲ Buy | Open Market | 3,000 | $15K | 8/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
MAIA Expands THIO-104 Trial to Spain, Portugal; Files Resale Prospectus
MAIA Biotechnology has broadened its pivotal Phase 3 THIO‑104 lung‑cancer trial to include Spain and Portugal after receiving regulatory clearance from the Spanish and Portuguese authorities. The company also filed a resale prospectus for 751,879 shares under its Clinical Trial Funding Agreement, providing additional capital for the study. These developments support the trial’s progression and expand patient access in key European markets.
MAIA Expands THIO-104 Trial to Spain, Portugal; Files Resale Prospectus. MAIA Biotechnology has broadened its pivotal Phase 3 THIO‑104 lung‑cancer trial to include Spain and Portugal after receiving regulatory clearance from the Spanish and Portuguese authorities. The company also filed a resale prospectus for 751,879 shares under its Clinical Trial Funding Agreement, providing additional capital for the study. These developments support the trial’s progression and expand patient access in key European markets.